Ariad Pharmaceuticals (ARIA) 7.75 $ARIA
Critical Alerts For Seadrill, Amgen, Ariad Pharmaceuticals, Johnson Controls and ACADIA Pharmaceuticals Released By InvestorsObserver
PR Newswire - Wed Jul 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SDRL, AMGN, ARIA, JCI and ACAD.
ACAD: 48.15 (-1.15), AMGN: 169.74 (-3.00), ARIA: 7.75 (-0.47), SDRL: 9.73 (+0.75), JCI: 45.06 (+0.62)
ARIAD to Receive up to $200 Million Through Iclusig Non-Dilutive Synthetic-Royalty Financing with PDL BioPharma
Business Wire - Wed Jul 29, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will receive $100 million in cash - $50 million upon deal execution late yesterday and an additional $50 million in one year - through a synthetic-royalty financing from PDL BioPharma, Inc. (NASDAQ: PDLI) in exchange for paying PDL a mid-single-digit royalty on future sales of Iclusig(R) (ponatinib) until PDL receives a fixed internal rate of return (IRR). ARIAD also has an option, in its discretion, to receive up to an additional $100 million at any time between 6 and 12 months from the date of the agreement, in one or two tranches on comparable terms.
ARIA: 7.75 (-0.47), PDLI: 5.83 (-0.06)
PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals
PR Newswire - Wed Jul 29, 6:35AM CDT
PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that it has entered into a revenue interest assignment agreement (the "Agreement"
in which it has agreed to provide ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) with up to $200 million in revenue interest financing in exchange for royalties on the net revenues of Iclusig® (ponatinib). Funding of the first $100 million will be made in two tranches of $50 million each, with the initial amount having already been funded on the closing date of the agreement and an additional $50 million to be funded on the 12-month anniversary of the closing date. In addition, ARIAD has an option to draw up to an additional $100 million at any time between the sixth and twelfth month anniversaries of the closing date.
ARIA: 7.75 (-0.47), PDLI: 5.83 (-0.06)
Is Ariad Pharmaceuticals a Cheap Stock?
Todd Campbell, The Motley Fool - Motley Fool - Fri Jul 24, 5:01PM CDT
Source: Ariad Pharmaceuticals Safety concerns fo r Ariad Pharmaceuticals ' Iclusig resulted in a temporary suspension of its sales in 2013, a more stringent prescribing label upon its commercial return in 2014, and a sagging share price that...
ARIA: 7.75 (-0.47)
US Blood Cancer Drug Market & Pipeline Analysis 2015
M2 - Wed Jul 22, 10:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hp4cd3/us_blood_cancer) has announced the addition of the "US Blood Cancer Drug Market & Pipeline Analysis 2015" report to their offering. Chemotherapeutic drugs are widely used therapeutics for the treatment of blood cancer in US. The future would witness a novel chemotherapeutics which are currently under various stages of research and development. Liposomal, pegylated and other improved versions are being made to offer higher therapeutic benefit along with minimized side effects. This will also help in increasing the number of indications and market volume by introduction of new chemotherapeutic products. They would have higher safety and efficacy levels as compared to their traditional counterparts. It will help in occupying large market shares and compete effectively with presently available drugs. Monoclonal antibodies are known for their superior pharmacological profiles and fewer side effects due to which they are widely accepted. Few monoclonal antibodies have been already introduced in US market. They have been able to generate significant revenues which are encouraging pharmaceutical companies to venture in this segment. Tyrosine kinase inhibitors are another major component of this market which has received lots of commercial success owing to their superior pharmacological efficacy. Both of them are far superior then chemotherapeutics and it is expected that blood cancer drugs belonging to different drug categories would be introduced in US market. Innovative blood cancer therapeutics is likely to generate huge revenues for the pharmaceutical companies in the next few years. However, few hurdles have to be passed like heterogeneous nature of blood cancer; it consists of different cells with different functions and it becomes difficult to eliminate them with single type of therapeutic. In this regard, only single therapeutic for different blood cancers have been introduced in US market till date. This strategy is likely to be followed by other pharmaceutical companies due to which competition in multiple blood cancer segments will increase. Market introduction of such therapeutics is likely to be widely accepted leading to generation of significant revenues. More blood cancer therapeutics is likely to enter in US market due to which its size will increase. "US Blood Cancer Drug Market & Pipeline Analysis 2015" Report Highlights: - Blood Cancer Incidence & Prevalence - Blood Cancer Drug Market Overview - Blood Cancer Drug Market Dynamics - Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline Insight - Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline: 435 Drugs - Majority Drugs in Phase-I Clinical Trials: 128 Drugs - Marketed Leukemia, Lymphoma & Myeloma Drug Clinical & Patent Analysis - Marketed Leukemia, Lymphoma & Myeloma Drug: 48 Drugs Key Topics Covered: 1. US Blood Cancer Incidence & Prevalence 2. US Blood Cancer Drug Market Overview 3. US Blood Cancer Drug Market Dynamics 4. US Blood Cancer Drug Market Future Prospects 5. Mechanism of Blood Cancer Therapeutics 6. Leukemia Drug Clinical Pipeline by Company & Phase 7. Marketed Leukemia Drug Clinical Insight 8. Lymphoma Drug Clinical Pipeline by Company & Phase 9. Marketed Lymphoma Drug Clinical Insight 10. Multiple Myeloma Drug Clinical Pipeline by Company & Phase 11. Marketed Multiple Myeloma Drug Clinical Insight 12. Multiple Blood Cancer Drug Clinical Pipeline by Company & Phase 13. Marketed Multiple Blood Cancer Drug Clinical Insight 14. Competitive Landscape - ARIAD Pharmaceuticals - Actelion Pharmaceuticals - Amgen - Astellas Pharma - Baxter BioScience - Bayer HealthCare Pharmaceuticals Inc. - Biogen Idec - Bristol-Myers Squibb - CASI Pharmaceuticals - Celera Genomics Group - Celgene Corporation - Eisai Co Ltd - Genmab - Gilead Sciences - GlaxoSmithKline - Hospira - Johnson & Johnson - Millennium Pharmaceuticals - Nova Laboratories - Novartis - Onxeo SA - Onyx Pharmaceuticals - Otsuka Pharmaceutical - Pfizer - Roche - SRI International - Scripps Clinic - Seattle Genetics - Southern Research Institute - Tekmira Pharmaceuticals Corporation - Teva Pharmaceutical Industries - Yakult Honsha For more information visit http://www.researchandmarkets.com/research/hp...ood_cancer
BIIB: 310.33 (-9.60), TKMR: 10.25 (-0.02), AMGN: 169.74 (-3.00), GSK: 42.80 (+1.09), BMY: 64.37 (-0.29), CASI: 1.53 (unch), JNJ: 99.85 (+0.83), GILD: 116.50 (+3.43), TEVA: 70.95 (-0.46), ARIA: 7.75 (-0.47), NVS: 103.77 (+0.98), CELGZ: 2.07 (+0.03)
ARIAD to Webcast Conference Call on Second Quarter 2015 Financial Results
Business Wire - Wed Jul 22, 6:34AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its second quarter 2015 financial results on Wednesday, August 5, 2015, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update.
ARIA: 7.75 (-0.47)
Equity Coverage on Biotechnology -- Aeterna Zentaris, Ariad Pharma, AVEO Pharma, Aduro BioTech, and 22nd Century Group
PR Newswire - Thu Jul 16, 8:10AM CDT
Equity Research Institute has initiated coverage on the following equities: Aeterna Zentaris Inc. (NASDAQ: AEZS), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), AVEO Pharmaceuticals Inc. (NASDAQ: AVEO), Aduro BioTech Inc. (NASDAQ: ADRO), and 22nd Century Group Inc. (AMEX: XXII). Free research report on Aeterna Zentaris can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=AEZS On Wednesday, July 15, 2015, the NASDAQ Composite ended at 5,098.94, down 0.12%, the Dow Jones Industrial Average edged 0.02% lower, to finish the day at 18,050.17, and the S&P 500 closed at 2,107.40, down 0.07%. The losses were broad based as six out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
XXII: 0.76 (+0.01), ADRO: 26.55 (-0.03), AVEO: 1.46 (-0.05), AEZS: 0.18 (-0.02), ARIA: 7.75 (-0.47)
United States Breast Cancer Therapy Market Opportunity Analysis
PR Newswire Europe - Wed Jul 15, 10:33AM CDT
Research and Markets(http://www.researchandmarkets.com/research/vk2qxr/us_breast_cancer [http://www.researchandmarkets.com/research/vk2qxr/us_breast_cancer]) has announced the addition of the "US Breast Cancer Therapy Market Opportunity Analysis" [http://www.researchandmarkets.com/research/vk2qxr/us_breast_cancer] report to their offering.
BMRN: 142.68 (-3.26), NAVB: 1.72 (unch), A: 40.30 (-0.15), MRK: 58.58 (+1.06), INCY: 101.95 (-3.54), ARIA: 7.75 (-0.47), NKTR: 12.35 (-0.53), DYAX: 24.45 (-0.62), NVS: 103.77 (+0.98), CELGZ: 2.07 (+0.03)
Critical Alerts For FireEye, Ariad Pharmaceuticals, ACADIA Pharmaceuticals, Esperion Therapeutics and Humana Released By InvestorsObserver
PR Newswire - Wed Jul 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FEYE, ARIA, ACAD, ESPR and HUM.
ESPR: 63.55 (-5.46), ACAD: 48.15 (-1.15), FEYE: 46.81 (+1.12), ARIA: 7.75 (-0.47), HUM: 182.70 (-1.82)
Orphan Drug Product Candidate Development Provides Revolutionary Solutions for Treatment of Severe Injuries and Innovative Therapies for Rare Diseases & Conditions
PR Newswire - Wed Jul 15, 7:15AM CDT
As modern biotechnology continues to provide breakthrough products and technologies to combat debilitating rare diseases, treat severe injuries and offer therapeutic treatments for many areas of various medical conditions, today's leading biotech & biopharmaceutical companies such as Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), EPIRUS Biopharmaceuticals, Inc. (NASDAQ: EPRS), ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), Celldex Therapeutics, Inc. (NASDAQ: CLDX) and Receptos, Inc. (NASDAQ: RCPT) race to introduce the newest technologies and products that help improve the lives and overall health of patients worldwide.
NVIV: 14.90 (-0.13), CLDX: 23.58 (-0.94), RCPT: 227.87 (+0.71), EPRS: 6.90 (-0.08), ARIA: 7.75 (-0.47), CELG: 132.88 (-2.54)
BUYINS.NET: ARIA SqueezeTrigger Price is $7.98. There is $364,614,804 That Short Sellers Still Need To Cover.
M2 - Mon Jul 13, 12:00PM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring ARIAD Pharmaceuticals Inc (NASDAQ:ARIA) in real time and just received an alert that ARIA is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 45350100 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $7.98. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
ARIA: 7.75 (-0.47)
Critical Alerts For Alibaba, Ariad Pharmaceuticals, Splunk, Receptos Inc. and Yelp Released By InvestorsObserver
PR Newswire - Wed Jul 01, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BABA, ARIA, SPLK, RCPT and YELP.
RCPT: 227.87 (+0.71), SPLK: 68.14 (-2.75), ARIA: 7.75 (-0.47), YELP: 24.29 (-9.22), BABA: 80.50 (-0.06)
BUYINS.NET: ARIA SqueezeTrigger Price is $7.98. There is $358,595,622 That Short Sellers Still Need To Cover.
M2 - Tue Jun 30, 11:31AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring ARIAD Pharmaceuticals Inc (NASDAQ:ARIA) in real time and just received an alert that ARIA is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 44629200 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $7.98. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
ARIA: 7.75 (-0.47)
ARIAD (ARIA) Presents Favorable Long-Term Data on Iclusig - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 15, 3:25PM CDT
ARIAD Pharmaceuticals (ARIA) presented encouraging long-term follow-up results from the pivotal phase II study (PACE) on Iclusig, at the European Hematology Association.
GILD: 116.50 (+3.43), ARIA: 7.75 (-0.47), BMY: 64.37 (-0.29), NVS: 103.77 (+0.98)
Look for Shares of Ariad Pharmaceuticals to Potentially Rebound after Yesterday's 2.42% Sell Off
Comtex SmarTrend(R) - Fri Jun 12, 4:57PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $8.53 to a high of $8.94. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $8.70 on volume of 3.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ARIA: 7.75 (-0.47)
ARIAD's Iclusig delivers long-term therapeutic benefit in blood cancer patients
Seeking Alpha - at Seeking Alpha - Fri Jun 12, 10:43AM CDT
ARIA: 7.75 (-0.47)
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial
Business Wire - Fri Jun 12, 10:15AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced long-term follow up from its pivotal Phase 2 trial of Iclusig(R) (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study now shows that with a median follow-up of approximately 3.5 years for chronic phase CML (CP-CML) patients and a median follow-up of approximately 2.9 years in all patients in the trial, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options. Responses have been maintained long-term in CP-CML patients. Eighty-three percent (83%) of CP-CML patients who achieved a major cytogenetic response (MCyR) are estimated to remain in MCyR at three years.
ARIA: 7.75 (-0.47)
Ariad Pharmaceuticals Shares Up 23.6% Since SmarTrend's Buy Recommendation (ARIA)
Comtex SmarTrend(R) - Fri Jun 12, 9:48AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on December 22nd, 2014 at $7.12. In approximately 6 months, Ariad Pharmaceuticals has returned 23.60% as of today's recent price of $8.80.
ARIA: 7.75 (-0.47)
Critical Alerts For Hewlett Packard, Illumina, Bitauto Holdings, GW Pharmaceuticals and Ariad Pharmaceuticals Released By InvestorsObserver
PR Newswire - Thu Jun 11, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for HPQ, ILMN, BITA, GWPH and ARIA.
GWPH: 113.45 (-0.52), ILMN: 215.25 (-2.57), ARIA: 7.75 (-0.47), HPQ: 30.34 (+0.07), BITA: 39.96 (+0.48)
Critical Alerts For Seadrill, Amgen, Ariad Pharmaceuticals, Johnson Controls and ACADIA Pharmaceuticals Released By InvestorsObserver
PR Newswire - Wed Jul 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SDRL, AMGN, ARIA, JCI and ACAD.
ACAD: 48.15 (-1.15), AMGN: 169.74 (-3.00), ARIA: 7.75 (-0.47), SDRL: 9.73 (+0.75), JCI: 45.06 (+0.62)
ARIAD to Receive up to $200 Million Through Iclusig Non-Dilutive Synthetic-Royalty Financing with PDL BioPharma
Business Wire - Wed Jul 29, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will receive $100 million in cash - $50 million upon deal execution late yesterday and an additional $50 million in one year - through a synthetic-royalty financing from PDL BioPharma, Inc. (NASDAQ: PDLI) in exchange for paying PDL a mid-single-digit royalty on future sales of Iclusig(R) (ponatinib) until PDL receives a fixed internal rate of return (IRR). ARIAD also has an option, in its discretion, to receive up to an additional $100 million at any time between 6 and 12 months from the date of the agreement, in one or two tranches on comparable terms.
ARIA: 7.75 (-0.47), PDLI: 5.83 (-0.06)
PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals
PR Newswire - Wed Jul 29, 6:35AM CDT
PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that it has entered into a revenue interest assignment agreement (the "Agreement"
in which it has agreed to provide ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) with up to $200 million in revenue interest financing in exchange for royalties on the net revenues of Iclusig® (ponatinib). Funding of the first $100 million will be made in two tranches of $50 million each, with the initial amount having already been funded on the closing date of the agreement and an additional $50 million to be funded on the 12-month anniversary of the closing date. In addition, ARIAD has an option to draw up to an additional $100 million at any time between the sixth and twelfth month anniversaries of the closing date. ARIA: 7.75 (-0.47), PDLI: 5.83 (-0.06)
Is Ariad Pharmaceuticals a Cheap Stock?
Todd Campbell, The Motley Fool - Motley Fool - Fri Jul 24, 5:01PM CDT
Source: Ariad Pharmaceuticals Safety concerns fo r Ariad Pharmaceuticals ' Iclusig resulted in a temporary suspension of its sales in 2013, a more stringent prescribing label upon its commercial return in 2014, and a sagging share price that...
ARIA: 7.75 (-0.47)
US Blood Cancer Drug Market & Pipeline Analysis 2015
M2 - Wed Jul 22, 10:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hp4cd3/us_blood_cancer) has announced the addition of the "US Blood Cancer Drug Market & Pipeline Analysis 2015" report to their offering. Chemotherapeutic drugs are widely used therapeutics for the treatment of blood cancer in US. The future would witness a novel chemotherapeutics which are currently under various stages of research and development. Liposomal, pegylated and other improved versions are being made to offer higher therapeutic benefit along with minimized side effects. This will also help in increasing the number of indications and market volume by introduction of new chemotherapeutic products. They would have higher safety and efficacy levels as compared to their traditional counterparts. It will help in occupying large market shares and compete effectively with presently available drugs. Monoclonal antibodies are known for their superior pharmacological profiles and fewer side effects due to which they are widely accepted. Few monoclonal antibodies have been already introduced in US market. They have been able to generate significant revenues which are encouraging pharmaceutical companies to venture in this segment. Tyrosine kinase inhibitors are another major component of this market which has received lots of commercial success owing to their superior pharmacological efficacy. Both of them are far superior then chemotherapeutics and it is expected that blood cancer drugs belonging to different drug categories would be introduced in US market. Innovative blood cancer therapeutics is likely to generate huge revenues for the pharmaceutical companies in the next few years. However, few hurdles have to be passed like heterogeneous nature of blood cancer; it consists of different cells with different functions and it becomes difficult to eliminate them with single type of therapeutic. In this regard, only single therapeutic for different blood cancers have been introduced in US market till date. This strategy is likely to be followed by other pharmaceutical companies due to which competition in multiple blood cancer segments will increase. Market introduction of such therapeutics is likely to be widely accepted leading to generation of significant revenues. More blood cancer therapeutics is likely to enter in US market due to which its size will increase. "US Blood Cancer Drug Market & Pipeline Analysis 2015" Report Highlights: - Blood Cancer Incidence & Prevalence - Blood Cancer Drug Market Overview - Blood Cancer Drug Market Dynamics - Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline Insight - Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline: 435 Drugs - Majority Drugs in Phase-I Clinical Trials: 128 Drugs - Marketed Leukemia, Lymphoma & Myeloma Drug Clinical & Patent Analysis - Marketed Leukemia, Lymphoma & Myeloma Drug: 48 Drugs Key Topics Covered: 1. US Blood Cancer Incidence & Prevalence 2. US Blood Cancer Drug Market Overview 3. US Blood Cancer Drug Market Dynamics 4. US Blood Cancer Drug Market Future Prospects 5. Mechanism of Blood Cancer Therapeutics 6. Leukemia Drug Clinical Pipeline by Company & Phase 7. Marketed Leukemia Drug Clinical Insight 8. Lymphoma Drug Clinical Pipeline by Company & Phase 9. Marketed Lymphoma Drug Clinical Insight 10. Multiple Myeloma Drug Clinical Pipeline by Company & Phase 11. Marketed Multiple Myeloma Drug Clinical Insight 12. Multiple Blood Cancer Drug Clinical Pipeline by Company & Phase 13. Marketed Multiple Blood Cancer Drug Clinical Insight 14. Competitive Landscape - ARIAD Pharmaceuticals - Actelion Pharmaceuticals - Amgen - Astellas Pharma - Baxter BioScience - Bayer HealthCare Pharmaceuticals Inc. - Biogen Idec - Bristol-Myers Squibb - CASI Pharmaceuticals - Celera Genomics Group - Celgene Corporation - Eisai Co Ltd - Genmab - Gilead Sciences - GlaxoSmithKline - Hospira - Johnson & Johnson - Millennium Pharmaceuticals - Nova Laboratories - Novartis - Onxeo SA - Onyx Pharmaceuticals - Otsuka Pharmaceutical - Pfizer - Roche - SRI International - Scripps Clinic - Seattle Genetics - Southern Research Institute - Tekmira Pharmaceuticals Corporation - Teva Pharmaceutical Industries - Yakult Honsha For more information visit http://www.researchandmarkets.com/research/hp...ood_cancer
BIIB: 310.33 (-9.60), TKMR: 10.25 (-0.02), AMGN: 169.74 (-3.00), GSK: 42.80 (+1.09), BMY: 64.37 (-0.29), CASI: 1.53 (unch), JNJ: 99.85 (+0.83), GILD: 116.50 (+3.43), TEVA: 70.95 (-0.46), ARIA: 7.75 (-0.47), NVS: 103.77 (+0.98), CELGZ: 2.07 (+0.03)
ARIAD to Webcast Conference Call on Second Quarter 2015 Financial Results
Business Wire - Wed Jul 22, 6:34AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its second quarter 2015 financial results on Wednesday, August 5, 2015, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update.
ARIA: 7.75 (-0.47)
Equity Coverage on Biotechnology -- Aeterna Zentaris, Ariad Pharma, AVEO Pharma, Aduro BioTech, and 22nd Century Group
PR Newswire - Thu Jul 16, 8:10AM CDT
Equity Research Institute has initiated coverage on the following equities: Aeterna Zentaris Inc. (NASDAQ: AEZS), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), AVEO Pharmaceuticals Inc. (NASDAQ: AVEO), Aduro BioTech Inc. (NASDAQ: ADRO), and 22nd Century Group Inc. (AMEX: XXII). Free research report on Aeterna Zentaris can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=AEZS On Wednesday, July 15, 2015, the NASDAQ Composite ended at 5,098.94, down 0.12%, the Dow Jones Industrial Average edged 0.02% lower, to finish the day at 18,050.17, and the S&P 500 closed at 2,107.40, down 0.07%. The losses were broad based as six out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
XXII: 0.76 (+0.01), ADRO: 26.55 (-0.03), AVEO: 1.46 (-0.05), AEZS: 0.18 (-0.02), ARIA: 7.75 (-0.47)
United States Breast Cancer Therapy Market Opportunity Analysis
PR Newswire Europe - Wed Jul 15, 10:33AM CDT
Research and Markets(http://www.researchandmarkets.com/research/vk2qxr/us_breast_cancer [http://www.researchandmarkets.com/research/vk2qxr/us_breast_cancer]) has announced the addition of the "US Breast Cancer Therapy Market Opportunity Analysis" [http://www.researchandmarkets.com/research/vk2qxr/us_breast_cancer] report to their offering.
BMRN: 142.68 (-3.26), NAVB: 1.72 (unch), A: 40.30 (-0.15), MRK: 58.58 (+1.06), INCY: 101.95 (-3.54), ARIA: 7.75 (-0.47), NKTR: 12.35 (-0.53), DYAX: 24.45 (-0.62), NVS: 103.77 (+0.98), CELGZ: 2.07 (+0.03)
Critical Alerts For FireEye, Ariad Pharmaceuticals, ACADIA Pharmaceuticals, Esperion Therapeutics and Humana Released By InvestorsObserver
PR Newswire - Wed Jul 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FEYE, ARIA, ACAD, ESPR and HUM.
ESPR: 63.55 (-5.46), ACAD: 48.15 (-1.15), FEYE: 46.81 (+1.12), ARIA: 7.75 (-0.47), HUM: 182.70 (-1.82)
Orphan Drug Product Candidate Development Provides Revolutionary Solutions for Treatment of Severe Injuries and Innovative Therapies for Rare Diseases & Conditions
PR Newswire - Wed Jul 15, 7:15AM CDT
As modern biotechnology continues to provide breakthrough products and technologies to combat debilitating rare diseases, treat severe injuries and offer therapeutic treatments for many areas of various medical conditions, today's leading biotech & biopharmaceutical companies such as Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), EPIRUS Biopharmaceuticals, Inc. (NASDAQ: EPRS), ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), Celldex Therapeutics, Inc. (NASDAQ: CLDX) and Receptos, Inc. (NASDAQ: RCPT) race to introduce the newest technologies and products that help improve the lives and overall health of patients worldwide.
NVIV: 14.90 (-0.13), CLDX: 23.58 (-0.94), RCPT: 227.87 (+0.71), EPRS: 6.90 (-0.08), ARIA: 7.75 (-0.47), CELG: 132.88 (-2.54)
BUYINS.NET: ARIA SqueezeTrigger Price is $7.98. There is $364,614,804 That Short Sellers Still Need To Cover.
M2 - Mon Jul 13, 12:00PM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring ARIAD Pharmaceuticals Inc (NASDAQ:ARIA) in real time and just received an alert that ARIA is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 45350100 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $7.98. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
ARIA: 7.75 (-0.47)
Critical Alerts For Alibaba, Ariad Pharmaceuticals, Splunk, Receptos Inc. and Yelp Released By InvestorsObserver
PR Newswire - Wed Jul 01, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BABA, ARIA, SPLK, RCPT and YELP.
RCPT: 227.87 (+0.71), SPLK: 68.14 (-2.75), ARIA: 7.75 (-0.47), YELP: 24.29 (-9.22), BABA: 80.50 (-0.06)
BUYINS.NET: ARIA SqueezeTrigger Price is $7.98. There is $358,595,622 That Short Sellers Still Need To Cover.
M2 - Tue Jun 30, 11:31AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring ARIAD Pharmaceuticals Inc (NASDAQ:ARIA) in real time and just received an alert that ARIA is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 44629200 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $7.98. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
ARIA: 7.75 (-0.47)
ARIAD (ARIA) Presents Favorable Long-Term Data on Iclusig - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 15, 3:25PM CDT
ARIAD Pharmaceuticals (ARIA) presented encouraging long-term follow-up results from the pivotal phase II study (PACE) on Iclusig, at the European Hematology Association.
GILD: 116.50 (+3.43), ARIA: 7.75 (-0.47), BMY: 64.37 (-0.29), NVS: 103.77 (+0.98)
Look for Shares of Ariad Pharmaceuticals to Potentially Rebound after Yesterday's 2.42% Sell Off
Comtex SmarTrend(R) - Fri Jun 12, 4:57PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $8.53 to a high of $8.94. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $8.70 on volume of 3.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ARIA: 7.75 (-0.47)
ARIAD's Iclusig delivers long-term therapeutic benefit in blood cancer patients
Seeking Alpha - at Seeking Alpha - Fri Jun 12, 10:43AM CDT
ARIA: 7.75 (-0.47)
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial
Business Wire - Fri Jun 12, 10:15AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced long-term follow up from its pivotal Phase 2 trial of Iclusig(R) (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study now shows that with a median follow-up of approximately 3.5 years for chronic phase CML (CP-CML) patients and a median follow-up of approximately 2.9 years in all patients in the trial, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options. Responses have been maintained long-term in CP-CML patients. Eighty-three percent (83%) of CP-CML patients who achieved a major cytogenetic response (MCyR) are estimated to remain in MCyR at three years.
ARIA: 7.75 (-0.47)
Ariad Pharmaceuticals Shares Up 23.6% Since SmarTrend's Buy Recommendation (ARIA)
Comtex SmarTrend(R) - Fri Jun 12, 9:48AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on December 22nd, 2014 at $7.12. In approximately 6 months, Ariad Pharmaceuticals has returned 23.60% as of today's recent price of $8.80.
ARIA: 7.75 (-0.47)
Critical Alerts For Hewlett Packard, Illumina, Bitauto Holdings, GW Pharmaceuticals and Ariad Pharmaceuticals Released By InvestorsObserver
PR Newswire - Thu Jun 11, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for HPQ, ILMN, BITA, GWPH and ARIA.
GWPH: 113.45 (-0.52), ILMN: 215.25 (-2.57), ARIA: 7.75 (-0.47), HPQ: 30.34 (+0.07), BITA: 39.96 (+0.48)
